Lupin gains on exclusive rights to sell Aptissen products in Canada

Shares of Lupin rose 1 percent intraday Thursday as company entered into definitive distribution agreement with Aptissen S.A. Lupin and Aptissen S.A. entered into a definitive distribution agreement under which Aptissen has granted Lupin the exclusive rights to market, distribute and sell the current Aptissen products in Canada, company said in BSE filing. This includes immediate rights to distribute Synolis VA for the treatment of Osteoarthritis. Synolis VA (Visco-Antalgic) is the intra-articular injection product for osteoarthritis with a unique combination of Hyaluronic Acid and high concentration of Sorbitol. Synolis VA 40/80 is already…

Read More